Bingham Osborn & Scarborough LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 3.7% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,424 shares of the company’s stock after buying an additional 403 shares during the quarter. Bingham Osborn & Scarborough LLC’s holdings in Johnson & Johnson were worth $1,701,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of JNJ. Winslow Evans & Crocker Inc. raised its stake in Johnson & Johnson by 0.3% during the second quarter. Winslow Evans & Crocker Inc. now owns 21,603 shares of the company’s stock worth $3,037,000 after purchasing an additional 69 shares during the period. Lathrop Investment Management Corp increased its holdings in shares of Johnson & Johnson by 1.4% during the 2nd quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock worth $689,000 after buying an additional 69 shares during the last quarter. Reik & CO. LLC raised its position in shares of Johnson & Johnson by 0.4% during the 2nd quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock valued at $2,493,000 after buying an additional 70 shares during the period. Delta Investment Management LLC grew its position in Johnson & Johnson by 1.0% in the second quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock worth $1,041,000 after acquiring an additional 71 shares during the period. Finally, IFG Advisory LLC grew its position in Johnson & Johnson by 0.4% in the second quarter. IFG Advisory LLC now owns 16,170 shares of the company’s stock worth $2,274,000 after acquiring an additional 71 shares during the period. Hedge funds and other institutional investors own 67.44% of the company’s stock.
Shares of NYSE:JNJ opened at $150.85 on Tuesday. Johnson & Johnson has a fifty-two week low of $109.16 and a fifty-two week high of $157.00. The firm’s 50 day moving average price is $145.39 and its 200 day moving average price is $146.58. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. The stock has a market cap of $397.12 billion, a price-to-earnings ratio of 23.72, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, November 23rd. This represents a $4.04 annualized dividend and a dividend yield of 2.68%. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the sale, the executive vice president now owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.27% of the company’s stock.
A number of equities analysts have recently weighed in on the company. Cantor Fitzgerald increased their price target on Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, August 19th. Finally, Credit Suisse Group raised their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company. Johnson & Johnson currently has an average rating of “Buy” and an average target price of $164.93.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Story: Municipal Bonds
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.